Gemcitabine and Cisplatin in the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer: Impact of Comorbidities on Safety and Efficacy Outcome

References

• Lee-Chiong TL Jr, Matthay RA. Lung cancer in the elderly patient. Clin Chest Med 1993; 14 (3): 453-478.
   Google Scholar
• Hennessy BT, Hanrahan EO, Breathnach OS. Chemotherapy options for the elderly patient with advanced non-small cell lung cancer. Oncologist 2003; 8 (3): 270–277.
   PubMed Web of Science ®Google Scholar
• Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of Vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999; 91 (1): 66-72.
   Google Scholar
• Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95 (5): 362–372.
   PubMed Web of Science ®Google Scholar
• Gillani AA, Grunberg SM. Aerorespiratory tract cancer in older patients. Semin Oncol 2004; 31 (2): 220–233.
   PubMed Web of Science ®Google Scholar
• Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17 (11): 3522–3530.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20 (21): 4285–4291.
   PubMed Web of Science ®Google Scholar
• Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 21 (17): 3207–3213.
   PubMed Web of Science ®Google Scholar
• Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005; 47 (1): 69–80.
   PubMed Web of Science ®Google Scholar
• Nguyen B, Sandler A, Denham C. The safety and effi-cacy of gemcitabine plus cisplatin in the elderly chemonive NSCLC patients (age70 years) as compared to those with age 70 years. Proc Am Soc Clin Oncol 1999; 18:471a (Abstr 1818).
   Google Scholar
• Lippe P, Silva RR, Giuliodori L, et al. Clinical benefit of gemcitabine-cisplatin in advanced non-small cell lung cancer elderly patients. Anticancer Res 2002; 22 (2B): 1053-1059.
   Google Scholar
• Berardi R, Porfiri E, Scartozzi M, et al. Elderly patients with advanced non-small cell lung cancer. A phase II study with weekly cisplatin and gemcitabine. Oncology 2003; 65 (3): 198–203.
   Google Scholar
• Feliu J, Martin G, Madronal C, et al. Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2003; 52 (3): 247–252.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method for classifying prognostic comorbidity in longitudi-nal studies: development and validation. J Chronic Dis 1987; 40 (5): 373–383.
   PubMedGoogle Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47 (1): 207–214.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
   Web of Science ®Google Scholar
• Bunn PA. Treatment of advanced non-small cell lung cancer with two drug combinations. J Clin Oncol 2003; 20 (17): 3565–3567.
   Web of Science ®Google Scholar
• Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non- small cell lung cancer guideline: Update 2003. J Clin Oncol 2004, 22 (2): 330–363
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from sur-veillance, epidemiology and end results-Medicare. J Clin Oncol 2004; 22 (24): 4971–4978
   PubMed Web of Science ®Google Scholar
• Rao AV, Seo PH, Cohen HJ. Geriatric assessment and comorbidity. Semin Oncol 2004; 31 (2): 149–159.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94 (3): 173–181.
   PubMed Web of Science ®Google Scholar
• Kelly K, Giarritta S, Hayes S, et al. Should older patients (pts) receive combinations chemotherapy for advanced non small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308. Proc Am Soc Clin Oncol 2001; 20: 329a (Abstr 1313).
   Google Scholar
• Langer CJ, Vangel M, Schiller J, et al. Age specific subanalysis of ECOG 1594: Fit elderly patients (70-80 yrs) with NSCLC do as well as younger patients (70). Lung Cancer 2003; 41: Suppl 2 (Abstr 49).
   Google Scholar
• Lilenbaum R, Herndon J, List M, et al. Single agent versus combination chemotherapy in advanced non small cell lung cancer: a CALGB randomized trial of efficacy, quality of life and cost effectiveness. Proc Am Soc Clin Oncol 2002; 21: la (Abstr 2).
   Google Scholar
• Fossella FV, Belani CP. Phase III study (TAX 326) of docetaxel-cisplatin (DC) and docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) for the first line treatment of advanced/metastatic non small cell lung cancer (NSCLC): analyses in the elderly patients. Proc Am Soc Clin. Oncol 2003; 22: 629 (Abstr 2528).
   Google Scholar
• Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. New Engl J Med 1999, 341 (27): 2061–2067.
   PubMed Web of Science ®Google Scholar
• Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years age or older in clinical trials. J Clin Oncol 2003, 21 (7): 1383–1389.
   PubMed Web of Science ®Google Scholar